Patents by Inventor Frank Luedicke

Frank Luedicke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diagnostic test for distinguishing the smoking status of a subject
    Patent number: 11630106
    Abstract: There is disclosed herein a device for determining the smoking status of a subject, wherein said device comprises a plurality of different specific binding molecules deposited to a solid phase to detect specifically the presence of two or three tobacco smoke exposure biomarkers in a biological sample, said biomarkers consisting of: (i) cotinine and total 4-(methylnitrosamino)-1-(3-, pyridyl)-1-butanol (NNAL); (ii) cotinine and N-acetyl-S-[2-carboxyethyl]-L-cysteine (CEMA); or (iii) cotinine and NNAL and CEMA.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 18, 2023
    Assignee: Philip Morris Products S.A.
    Inventors: Frank Luedicke, Manuel C. Peitsch
  • DIAGNOSTIC TEST FOR DISTINGUISHING THE SMOKING STATUS OF A SUBJECT
    Publication number: 20200141933
    Abstract: There is disclosed herein a device for determining the smoking status of a subject, wherein said device comprises a plurality of different specific binding molecules deposited to a solid phase to detect specifically the presence of two or three tobacco smoke exposure biomarkers in a biological sample, said biomarkers consisting of: (i) cotinine and total 4-(methylnitrosamino)-1-(3-, pyridyl)-1-butanol (NNAL); (ii) cotinine and N-acetyl-S-[2-carboxyethyl]-L-cysteine (CEMA); or (iii) cotinine and NNAL and CEMA.
    Type: Application
    Filed: May 18, 2018
    Publication date: May 7, 2020
    Inventors: Frank Luedicke, Manuel C. Peitsch
  • Composition for contraception
    Patent number: RE37564
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: February 26, 2002
    Assignee: Schering Aktiengesellschaft
    Inventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
  • Composition for contraception
    Patent number: RE37838
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: February 15, 2000
    Date of Patent: September 10, 2002
    Assignee: Schering Aktiengesellschaft
    Inventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke
  • Composition for contraception
    Patent number: RE38253
    Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17&bgr;-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 2.5 to 3.0 mg of drospirenone and 0.1 to 0.2 1 to 2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.
    Type: Grant
    Filed: February 25, 2002
    Date of Patent: September 16, 2003
    Assignee: Schering Aktiengesellschaft
    Inventors: Jürgen Spona, Bernd Düsterberg, Frank Lüdicke